Laboratory of Avian Medicine, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.
Appl Microbiol Biotechnol. 2011 Feb;89(4):893-902. doi: 10.1007/s00253-010-2973-9. Epub 2010 Nov 10.
Influenza is a pandemic contagious disease and causes human deaths and huge economic destruction of poultry in the world. In order to control and prevent influenza, mainly type A, influenza vaccine for human and poultry were available since the 1940s and 1920s, respectively. In the development of vaccine production, influenza viruses were cultured originally from chicken embryos to anchorage-dependent cell lines, such as MDCK and Vero. The anchorage-independent lines have also been used to produce influenza virus, such as PER.C6 and engineering modified MDCK and Vero. During the process of influenza vaccine production, the common problem faced by all producers is how to improve the titer of influenza virus. This paper focuses on the developments of cell culture for influenza virus vaccine production, limitations of cell culture, and relative strategies for improvement virus yields in cell-culture systems.
流感是一种具有全球流行性的传染性疾病，可导致人类死亡，并对禽类养殖业造成巨大的经济损失。为了控制和预防流感，自 20 世纪 40 年代和 20 世纪 20 年代起，分别出现了针对人类和禽类的甲型流感疫苗。在疫苗生产的发展过程中，流感病毒最初是从鸡胚中培养出来的，然后转移到了贴壁依赖性细胞系，如 MDCK 和 Vero 中。无血清悬浮培养也已被用于生产流感病毒，如 PER.C6 和工程改造的 MDCK 和 Vero。在流感疫苗生产过程中，所有生产商共同面临的一个常见问题是如何提高流感病毒的滴度。本文主要介绍流感病毒疫苗生产的细胞培养进展、细胞培养的局限性，以及提高细胞培养系统中病毒产量的相关策略。
